|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.383 USD | +4.19% |
|
-0.91% | -92.69% |
| 05-07 | Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50 | MT |
| 05-07 | HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy | MT |
On April 15, 2024, Edward T. Anderson resigned from the Board of Directors of Lyra Therapeutics, Inc. (the ? Company?) as well as the Audit Committee and Compensation Committee of the Board. Mr. Anderson has been involved with the Company as an investor and adviser since 2006 and as a Board member since 2019.
On April 15, 2024, the Board appointed Nancy L. Snyderman to the Audit Committee of the Board.
| 1st Jan change | Capi. | |
|---|---|---|
| -92.69% | 22.41M | |
| +33.63% | 50.85B | |
| -0.09% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +11.18% | 26.11B | |
| -21.95% | 19.13B | |
| +8.61% | 13.05B | |
| +28.31% | 12.16B | |
| +24.73% | 12.08B |
LYRA THERAPEUTICS, INC. 
